Immunocore Holdings plc
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $400.0M | $310.2M | $249.4M | $174.4M | $36.5M |
| Cost of Revenue | $5.1M | $2.7M | $1.0M | $1.1M | $0 |
| Gross Profit | $394.9M | $307.5M | $248.4M | $173.3M | $36.5M |
| Gross Margin | 98.7% | 99.1% | 99.6% | 99.4% | 100.0% |
| Operating Expenses | |||||
| Research & Development | $274.9M | $222.2M | $163.5M | $101.9M | $100.2M |
| SG&A Expense | $165.4M | $155.8M | $144.5M | $123.1M | $110.8M |
| Operating Income | $-45.4M | $-70.5M | $-59.6M | $-51.7M | $-174.6M |
| Operating Margin | -11.3% | -22.7% | -23.9% | -29.7% | -478.5% |
| Interest Expense | $12.2M | $18.8M | $5.2M | $5.4M | $5.6M |
| Pretax Income | $-19.1M | $-52.9M | $-60.9M | $-40.9M | $-179.9M |
| Income Tax Expense | $16.4M | $-1.9M | $-5.6M | $11.7M | $150.0K |
| Net Income | $-35.5M | $-51.1M | $-55.3M | $-52.5M | $-180.0M |
| Net Margin | -8.9% | -16.5% | -22.2% | -30.1% | -493.4% |
| EPS (Basic) | $-0.71 | $-1.02 | $-1.13 | $-1.15 | $-4.24 |
| EPS (Diluted) | $-0.71 | $-1.02 | $-1.13 | $-1.15 | $-4.24 |
| Shares Outstanding (Basic) | 50.3M | 50.0M | 48.9M | 45.7M | 42.5M |
| Shares Outstanding (Diluted) | 50.3M | 50.0M | 48.9M | 45.7M | 42.5M |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | — |